Reply

Affiliations

Comment

Kenneth G Saag et al. Arthritis Rheumatol. 2019 Oct.

. 2019 Oct;71(10):1771-1772.

doi: 10.1002/art.41013. Epub 2019 Sep 2.

No abstract available

Comment on

Denosumab Versus Risedronate in Glucocorticoid-Induced Osteoporosis: Final Results of a Twenty-Four-Month Randomized, Double-Blind, Double-Dummy Trial.
Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF. Saag KG, et al. Arthritis Rheumatol. 2019 Jul;71(7):1174-1184. doi: 10.1002/art.40874. Epub 2019 May 25. Arthritis Rheumatol. 2019. PMID: 30816640 Free PMC article. Clinical Trial.
Bisphosphonates as a First-Line Treatment for Glucocorticoid-Induced Osteoporosis: Comment on the Article by Saag et al.
Gonzalez-Rodriguez E, Aubry-Rozier B, Stoll D, Lamy O. Gonzalez-Rodriguez E, et al. Arthritis Rheumatol. 2019 Oct;71(10):1770-1771. doi: 10.1002/art.41016. Epub 2019 Aug 29. Arthritis Rheumatol. 2019. PMID: 31215777 No abstract available.
Where Does Denosumab Stand in the Treatment of Glucocorticoid-Induced Osteoporosis? Comment on the Article by Saag et al.
Chattopadhyay A, Sharma SK, Sharma A, Jain S, Dhir V. Chattopadhyay A, et al. Arthritis Rheumatol. 2019 Oct;71(10):1770. doi: 10.1002/art.41015. Epub 2019 Aug 29. Arthritis Rheumatol. 2019. PMID: 31216125 No abstract available.

1. Cummings SR, Ferrari S, Eastell R, Gilchrist N, Jensen JB, McClung M, et al. Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. J Bone Miner Res 2018;33:190-8.
1. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, et al. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension. Lancet Diabetes Endocrinol 2017;5:513-23.
1. Dore RK, Cohen SB, Lane NE, Palmer W, Shergy W, Zhou L, et al. Effects of denosumab on bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates. Ann Rheum Dis 2010;69:872-5.
1. Saag KG, McDermott MT, Adachi J, Lems W, Lane NE, Geusens P, et al. Effect of discontinuation of denosumab in subjects with rheumatoid arthritis treated with glucocorticoids. Ann Rheum Dis 2019;78 Suppl 2:A931.
1. Chapurlat R. Effects and management of denosumab discontinuation. Joint Bone Spine 2018;85:515-7.